Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03066661 |
Expanded Access Status :
No longer available
First Posted : February 28, 2017
Last Update Posted : April 26, 2019
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Cancers With NTRK, ROS1, or ALK Gene Fusions | Drug: Entrectinib |
Study Type : | Expanded Access |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions |
- Drug: Entrectinib
Open-label expanded access, capsulesOther Name: RXDX-101
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
- Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
- Willing and able to provide written, signed informed consent
- Medically suitable for treatment with entrectinib (RXDX-101)
Exclusion Criteria:
- Currently enrolled in an ongoing clinical study with any other investigational agent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03066661
United States, California | |
1-844-Startrk (782-7875) | |
San Diego, California, United States, 92121 |
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT03066661 |
Other Study ID Numbers: |
Entrectinib (RXDX-101) - EAP |
First Posted: | February 28, 2017 Key Record Dates |
Last Update Posted: | April 26, 2019 |
Last Verified: | April 2019 |
Entrectinib Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |